Frexalimab reduces plasma neurofilament light chain in relapsing multiple sclerosis: Week 48 data from a phase 2 trial

Authors
Category Primary study
Conference10th Congress of the European Academy of Neurology
Year 2024
This article has no abstract
Epistemonikos ID: 2c784650be24405ced07b9f4632bbc3bfa79b83b
First added on: Jan 10, 2026